Summary
Определение
Анамнез и осмотр
Ключевые диагностические факторы
- presence of risk factors
- typical skin lesions
- nerve involvement
- sensory loss
Другие диагностические факторы
- immunological reactions
- eye lesions
Факторы риска
- close contact with a person with multibacillary leprosy
- poverty
- residence in endemic area
- genetic predisposition
- zoonotic transmission
Диагностические исследования
Исследования, которые показаны в первую очередь
- skin smear
- skin and/or nerve biopsy and histopathology
Исследования, проведение которых нужно рассмотреть
- polymerase chain reaction
Алгоритм лечения
multibacillary (MB) or paucibacillary (PB): no rifampicin or fluoroquinolone resistance
multibacillary (MB) or paucibacillary (PB): rifampicin ± fluoroquinolone resistance
type 1 reaction (reversal reaction)
type 2 reaction (erythema nodosum leprosum)
Lucio's phenomenon
Составители
Авторы
Maria T. Ochoa, MD
Clinical Professor of Dermatology
USC Keck School of Medicine
Department of Dermatology
Los Angeles
CA
Раскрытие информации
MTO declares that she has no competing interests.
Выражение благодарностей
Dr Maria T. Ochoa would like to gratefully acknowledge Dr Denis Paul Jacques Daumerie, a previous contributor to this topic. DPJD declares that he has no competing interests.
Рецензенты
Hubert Sansarricq, MD
Member of World Health Organization Panel of Experts on Leprosy
Saint-Armour Morlaas
France
Раскрытие информации
HS declares that he has no competing interests.
David M. Scollard, MD, PhD
Chief
Clinical Branch
National Hansen's Disease Programs
Baton Rouge
LA
Раскрытие информации
DMS declares that he has no competing interests.
Alexandre Tiendrebéogo, MD, MPH
Medical Officer
Leprosy and Neglected Tropical Diseases in Central Africa Countries
World Health Organization
Country Office of Kinshasa
DR of Congo
Раскрытие информации
AT declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
World Health Organization. Towards zero leprosy. Global leprosy (Hansen’s Disease) strategy 2021-2030. Apr 2021 [internet publication].Full text
World Health Organization. Implementation of MDT. In: Multidrug therapy against leprosy: development and implementation over the past 25 years. Geneva: World Health Organization; 2004:45-68.Full text
World Health Organization. Guidelines for the diagnosis, treatment and prevention of leprosy. Oct 2018 [internet publication].Full text
World Health Organization. Leprosy/Hansen disease: management of reactions and prevention of disabilities. 2020 [internet publication].Full text
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

დიფერენციული დიაგნოზები
- Psoriasis
- Eczema
- Tinea corporis
More Differentialsგაიდლაინები
- Towards zero leprosy. Global leprosy (Hansen’s Disease) strategy 2021-2030
- Leprosy/Hansen disease: Contact tracing and post-exposure prophylaxis
More გაიდლაინებიშედით სისტემაში ან გამოიწერეთ BMJ Best Practice
ამ მასალის გამოყენება ექვემდებარება ჩვენს განცხადებას